ChromaDex to begin the first human trials
date:Apr 22, 2013
wo individual components alone. Recently, caffeinated energy products have been coming under increased regulatory and political scrutiny regarding the possible risks of consuming high amounts of caffeine, the company said: this patented new ingredient technology should allow formulators of caffeinated energy products the opportunity to reduce the total amount of caffeine without affecting the consumers' product experience.

The human study is intended to confirm an earlier animal study which sho
2/4 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
06/30 17:36